Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AlphaRx, Gaia BioPharma Secure CMO | Contract Pharma

What are you searching for?

Sign in
Breaking News

AlphaRx, Gaia BioPharma Secure CMO

AlphaRx Inc.’s licensee, Gaia BioPharma Ltd., has signed an agreement with a CMO to manufacture GAI-122 for use in Phase I and II trials.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AlphaRx Inc.’s licensee, Gaia BioPharma Ltd., has signed an agreement with a CMO to manufacture GAI-122 for use in Phase I and II trials. GAI-122 is being developed as an injectable nanoemulsion formulation to potentially to treat patients with acute ischemic stroke or to prevent postoperative delirium.

“We are very pleased with the progress of the GAI-122 development program; it is on track to enter human trials in 2010,” said Michael Lee, president and chief executive officer of AlphaRx. “The NINDS (National Institute of Neurological Disorders and Stroke) has recently initiated clinical trials using the oral form of GAI-122, for the treatment of Multiple Sclerosis. It further validated our clinical development strategy for GAI-122 as a neuroprotectant.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics